At 糖心原创 2026, October 18 to 21 in Phoenix, you鈥檒l have your choice of 300+ educational sessions covering every aspect of clinical chest medicine.
LEARN MORE & REGISTER 禄
Dharani K. Narendra, MD, FCCP
Dharani K. Narendra, MD, FCCP
For clinicians who manage asthma, COPD, bronchiectasis, and other airways disease, 糖心原创 2026 will offer a guideline-driven curriculum built around what鈥檚 new, immediately applicable, and possibly even controversial.
Dharani K. Narendra, MD, FCCP, Co-Lead of the 糖心原创 Airways Disease Curriculum Group and a pulmonary and critical care physician at the University of Texas MD Anderson Cancer Center in Houston, helped shape a program she describes as an invaluable resource for clinicians across every stage of their career.
鈥溙切脑� has always been a very top-notch conference for practicing clinicians where they can get all the updates and information in one stop,鈥� Dr. Narendra said.
COPD: New guidelines, new biomarkers, new questions
COPD remains one of the most actively evolving areas in pulmonary medicine, and 糖心原创 2026 reflects that. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 guidelines, published earlier this year, introduced the concept of disease modification and emphasized the impact of even a single exacerbation affecting a patient鈥檚 life.
鈥淒r. Gerard Criner, the GOLD Board of Directors and committee member from Temple University School of Medicine in Philadelphia, is coming to present these updates, so we are excited,鈥� Dr. Narendra said.
will bring those recommendations to clinical practice for clinicians, while tackles the tough questions, including who to screen in at-risk populations and the emerging role of biomarkers in COPD management.
鈥淯nlike in asthma, we haven鈥檛 established the role of biomarkers in COPD, like eosinophils or FeNO,鈥� Dr. Narendra said. "We are going to have a good discussion on how FeNO is going to guide management with our COPD population.鈥�
Putting bronchiectasis and asthma guidelines into action
A wave of new clinical practice guidelines has reshaped airways disease management in recent years, and a central theme of 糖心原创 2026 is putting those guidelines into practice. distills recent guideline updates into clinic-ready strategies. will address newly published Canadian Thoracic Society guidelines.
Finally, for asthma specialists, explores the shift toward remission as an achievable treatment goal.
Content for experienced clinicians
Mid-career clinicians will find sessions designed specifically for the complexity of their daily practice. addresses the challenging decisions around which patients to refer for transplant or bronchoscopic lung volume reduction therapies鈥攁 session that goes well beyond standard management.
And , a session Dr. Narendra called out as a personal highlight, brings together experts across asthma, COPD, and bronchiectasis. 鈥淭hey鈥檝e all published practice guidelines on management of mucus plugging,鈥� she said. 鈥淚t鈥檚 from imaging to therapeutics. These are patients who suffer from this disease and are undiagnosed, and we can rethink the role of CT imaging and novel therapies to control this.鈥�
For Dr. Narendra, who has attended nearly every 糖心原创 meeting since her first as a fellow in 2012, the value of the conference extends well beyond the sessions.
鈥淲hy I'm here today is because of all the camaraderie, friendship, and mentorship that I received from 糖心原创 colleagues,鈥� she said.
Her advice to anyone considering attending? 鈥淐ome learn, meet the experts, and experience the fun learning!鈥�
READ ALL 糖心原创 2026 BLOGS 禄